We are monitoring the impact of COVID-19 on MEA Biosimilars Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1083
Share on
Share on

Middle East & Africa Biosimilars Market Research Report – Segmented By Type, By Technology, By Application, By Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Growth, Trends, Forecast | 2021 to 2026

Pulished: April, 2021
ID: 1083
Pages: 145

MEA Biosimilars Market Size (2021 to 2026)

The size of the Middle East and Africa Biosimilars Market is forecasted to grow from USD 2.17 billion by 2026 from USD 0.71 billion in 2021, growing at a CAGR of 24.96% from 2021 to 2026. Rising demand to increase the number of research centers in developed countries elevates the growth rate of the market in this region.

Biosimilars are emerging as one of the most important sectors in the healthcare industry. With increasing healthcare costs, biosimilars are being looked upon as an affordable treatment option. Growing economies are observing comprehensive growth in the biosimilars industry from demanding clinical needs of therapeutics. The rise in GDP and healthcare expenditures and the demand for cost-effective therapeutics solutions have resulted in this market's growth.

Biosimilars are made using living cells that treat disease by recombinant DNA technology and controlled gene expression. Most biosimilars are derived from bacteria, viruses, plants, and animals. Biosimilar drugs are used to prevent and cure various diseases such as rheumatoid arthritis, cancer, chronic kidney failure, oncology, diabetes, heart attacks, autoimmune diseases, growth hormone deficiency, and infectious disease.

Biosimilars offer a cheaper alternative to other biological and synthetic drugs. The main health challenges within the Middle East and African region are beginning to reflect those in Western countries, with diabetes highly prevalent, with more than 1 in 10 adults suffering from it, and cancer-related mortality rates increasing. Economies in this region vary from country to country. While some countries in the region have been able to modify their healthcare expenditure to provide biosimilar therapies, others – such as Egypt and Algeria – are struggling. Government support and initiatives play a crucial role. Emerging pharmaceutical markets and lenient government regulations provide some of the major openings in this is market. However, high manufacturing cost and complexity and the availability of low-priced generic drugs in the market are some of the market's major restraints.

This research report on the MEA biosimilars market has been segmented and sub-segmented the market into the following categories:

By Product Type:

  • Protein
  • Insulin
  • Human Growth Hormones
  • Granulocyte Colony-stimulating Factor (G-CSF)
  • Interferons
  • Recombinant Glycosylated Proteins
  • Erythropoietin
  • Monoclonal Antibodies
  • Follitropin
  • Recombinant Peptides
  • Glucagon

By Technology:

  • Mass Spectroscopy
  • Chromatography
  • Monoclonal Antibody Technology
  • Recombinant DNA Technology
  • Nuclear Magnetic resonance (NMR) technology
  • Electrophoresis
  • Bioassay

By Disease:

  • Oncology Diseases
  • Blood Disorders
  • Growth hormone deficiencies
  • Chronic and autoimmune diseases
  • Others

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Regionally, awareness of biosimilars and research in the MEA region continues to grow, with the clinical trials of biosimilars already taking place in some countries, most notably Jordan. As a result, the possibility of an increase in interest in biosimilars across these nations is very likely.

KEY MARKET PLAYERS:

Companies like Sandoz International GmbH, Wockhardt Ltd, Hospira, Inc., Teva Pharmaceutical Industries Ltd. Dr. Reddy’s Laboratories, Biocon Limited, Mylan, Inc., Zydus Cadila, Celltrion Inc., Roche Diagnostics, and Cipla Ltd are playing an important role in the MEA Biosimilars Market.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Type                        

                                5.1.1 Protein     

                                5.1.2 Insulin       

                                5.1.3 Human Growth Hormones

                                5.1.4 Granulocyte Colony-stimulating Factor (G-CSF)       

                                5.1.5 Interferons             

                                5.1.6 Recombinant Glycosylated Proteins             

                                5.1.7 Erythropoietin       

                                5.1.8 Monoclonal Antibodies     

                                5.1.9 Follitropin

                                5.1.10 Recombinant Peptides    

                                5.1.11 Glucagon               

                                5.1.12 Calcitonin              

                5.2 By Technology                          

                                5.2.1 Mass Spectroscopy             

                                5.2.2 Chromatography  

                                5.2.3 Monoclonal Antibody Technology

                                5.2.4 Recombinant DNA Technology       

                                5.2.5 Nuclear magnetic resonance (NMR) technology     

                                5.2.6 Electrophoresis     

                                5.2.7 Bioassay   

                5.3 By Application                           

                                5.3.1 Oncology diseases

                                5.3.2 Blood disorders    

                                5.3.3 Growth hormone deficiencies        

                                5.3.4 Chronic and autoimmune diseases

                                5.3.5 Others      

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 Middle-East                                

                6.3 Africa                            

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Sandoz International GmbH                

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Wockhardt                 

                8.3 Hospira                        

                8.4 Teva Pharmaceutical Industries                         

                8.5 Dr. Reddy’s Laboratories                      

                8.6 Biocon                          

                8.7 Mylan                           

                8.8 Zydus Cadila                               

                8.9 Celltrion                       

                8.10 Roche Diagnostics                 

                8.11 Cipla                            

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

                                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East & Africa Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  2. Middle East & Africa Protein Market, By Region, From 2021 to 2026 (USD Million)
  3. Middle East & Africa Insulin Market, By Region, From 2021 to 2026 (USD Million)
  4. Middle East & Africa Human Growth Hormones Market, By Region, From 2021 to 2026 (USD Million)
  5. Middle East & Africa Granulocyte Colony-stimulating Factor (G-CSF) Market, By Region, From 2021 to 2026 (USD Million)
  6. Middle East & Africa Interferons Market, By Region, From 2021 to 2026 (USD Million)
  7. Middle East & Africa Recombinant Glycosylated Proteins Market, By Region, From 2021 to 2026 (USD Million)
  8. Middle East & Africa Erythropoietin Market, By Region, From 2021 to 2026 (USD Million)
  9. Middle East & Africa Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  10. Middle East & Africa Follitropin Market, By Region, From 2021 to 2026 (USD Million)
  11. Middle East & Africa Recombinant Peptides Market, By Region, From 2021 to 2026 (USD Million)
  12. Middle East & Africa Glucagon Market, By Region, From 2021 to 2026 (USD Million)
  13. Middle East & Africa Calcitonin Market, By Region, From 2021 to 2026 (USD Million)
  14. Middle East & Africa Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  15. Middle East & Africa Mass Spectroscopy Market, By Region, From 2021 to 2026 (USD Million)
  16. Middle East & Africa Chromatography Market, By Region, From 2021 to 2026 (USD Million)
  17. Middle East & Africa Monoclonal Antibody Technology Market, By Region, From 2020 - 2025 (USD Million)
  18. Middle East & Africa Recombinant DNA Technology Market, By Region, From 2021 to 2026 (USD Million)
  19. Middle East & Africa Nuclear magnetic resonance (NMR) technology Market, By Region, From 2021 to 2026 (USD Million)
  20. Middle East & Africa Electrophoresis Market, By Region, From 2021 to 2026 (USD Million)
  21. Middle East & Africa Bioassay Market, By Region, From 2021 to 2026 (USD Million)
  22. Middle East & Africa Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  23. Middle East & Africa Oncology diseases Market, By Region, From 2021 to 2026 (USD Million)
  24. Middle East & Africa Blood disorders Market, By Region, From 2021 to 2026 (USD Million)
  25. Middle East & Africa Growth hormone deficiencies Market, By Region, From 2021 to 2026 (USD Million)
  26. Middle East & Africa Chronic and autoimmune diseases Market, By Region, From 2021 to 2026 (USD Million)
  27. Middle East & Africa Others Market, By Region, From 2021 to 2026 (USD Million)
  28. Middle East Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  29. Middle East Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  30. Middle East Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  31. Africa Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  32. Africa Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  33. Africa Biosimilars Market, By Application, From 2021 to 2026 (USD Million)

 

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample